Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term gastrointestinal stromal tumors. Found 9 abstracts

Indio V, Astolfi A, Tarantino G, Urbini M, Patterson J, Nannini M, Saponara M, Gatto L, Santini D, do Valle IF, Castellani G, Remondini D, Fiorentino M, von Mehren M, Brandi G, Biasco G, Heinrich MC, Pantaleo MA. Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene. International journal of molecular sciences. 2018 Mar 04;19(3).   PMCID: PMC5877593
Cauchi C, Somaiah N, Engstrom PF, Litwin S, Lopez M, Lee J, Davey M, Bove B, von Mehren M. Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib. Cancer Chemotherapy and Pharmacology. 2012 Apr;69(4):977-82.   PMCID: PMC3313017
Patson B, Cohen RB, Olszanski AJ. Pharmacokinetic evaluation of axitinib. Expert Opinion on Drug Metabolism & Toxicology. 2012 Feb;8(2):259-70.   PMCID: not NIH funded
von Mehren M, Benjamin RS, Bui MM, Casper ES, Conrad EU, DeLaney TF, Ganjoo KN, George S, Gonzalez R, Heslin MJ, Kane JM, Mayerson J, McGarry SV, Meyer C, O'Donnell RJ, Paz IB, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Shankar S, Van Tine BA, Wayne J, Sundar H, McMillian NR. Soft Tissue Sarcoma, Version 2.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2012 Aug;10(8):951-60.   PMCID: not NIH funded
Blay JY, von Mehren M. Nilotinib: A Novel, Selective Tyrosine Kinase Inhibitor. Seminars in Oncology. 2011 Apr;38(2):S3-S9.   PMCID: not NIH funded
Pisters PW, Blanke CD, von Mehren M, Picus J, Sirulnik A, Stealey E, Trent JC. A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices. Annals of Oncology. 2011 Nov;22(11):2523-9.   PMCID: not NIH funded
Demetri GD, Antonia S, Benjamin RS, Bui MM, Casper ES, Conrad EU, DeLaney TF, Ganjoo KN, Heslin MJ, Hutchinson RJ, Kane JM, Letson GD, McGarry SV, O'Donnell RJ, Paz IB, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schupak KD, Schwartz HS, Thornton K, von Mehren M, Wayne J. Soft Tissue Sarcoma. Journal of the National Comprehensive Cancer Network. 2010 Jun;8(6):630-74.   PMCID: not NIH funded
de Camargo VP, van de Rijn M, de Alava E, Madoz-Gurpide J, Pilotti S, von Mehren M, Pedeutour F, Maki RG, Rutkowski P, Thomas DM. Other Targetable Sarcomas. Seminars in Oncology. 2009 Aug;36(4):358-71.   PMCID: not NIH funded
von Mehren M. Targeted therapy with imatinib: Hits and misses?. Journal of Clinical Oncology. 2005 Jan;23(1):8-10.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term gastrointestinal stromal tumors

gastrointestinal stromal tumors imatinib mesylate phase-ii mutations phase-ii trial giant-cell tumor sarcoma desmoid tumor tyrosine kinase c-kit radiation-therapy monoclonal-antibody kaposis-sarcoma positron-emission-tomography trial inhibitor VEGFR axitinib fibromatosis of-function mutations dose imatinib european-organization cell lung-cancer clinical-response differential mouse model imatinib-resistant soft tissue chemotherapy 2008 matteo d-p am soc clin oncol-v26 D842v multikinase angiogenesis 2008 orge s-j clin oncol-v26 chronic myelogenous leukemia registry Gist antitumor-activity sensitivity of-function vascular endothelial growth factor growth-factor receptor chronic myeloid-leukemia survival growth contrast-enhanced mri 1989 sner mc-archives of surgery-v124-p191 bcr-abl diastolic blood-pressure soft tissue extremity sarcoma GIST AG-013736 soft part prognostic-factors in-vitro activity Tyrosine kinase inhibitor neoadjuvant chemotherapy amn107 nilotinib retroperitoneal sarcomas spectrometry-based proteomics colorectal-cancer chronic dermatofibrosarcoma protuberans Kit mutations VEGF solid tumors renal-cell carcinoma declare no conflict of interest gist mutation diagnosis Nilotinib adjuvant imatinib NCCN Guidelines kit Secondary Pdgfra 2003 silva cm-pathol oncol res-v9-p13 long-term outcomes mesylate wild-type metastatic radiation therapy endothelial growth-factor NCCN Clinical Practice Guidelines surgery 2007 orge s-j clin oncol-v25 myeloid-leukemia primary extremity sarcoma crenolanib endothelial-cells angiogenesis inhibitor Kit
Last updated on Wednesday, March 04, 2020